4D Molecular Therapeutics’ License Agreement with Astellas Pharma

Pietro Martinoia
Tagged:

Latham & Watkins advises 4D Molecular Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Pietro Martinoia

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here